Multiple Myeloma and Environmental Exposure to Pesticides in the French West Indies: A Population Based Case-control Study.
- Status
- UNKNOWN
- Phase
- N/A
Clinical Trials Related to Multiple Myeloma
Related studies linked through entity extraction aliases.
A Study of Pembrolizumab Added to the Standard First-Line Therapy of Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) for NDMM NTE
- Status
- WITHDRAWN
- Phase
- PHASE2
Effects of Early Palliative Care Integration on Patients With Newly Diagnosed Multiple Myeloma
- Status
- COMPLETED
- Phase
- NA
Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
A Safety and Efficacy Study Evaluating CTX120 in Subjects With Relapsed or Refractory Multiple Myeloma
- Status
- TERMINATED
- Phase
- PHASE1
Study of Pomalidomide, Oral Dexamethasone and Very Low-dose Cyclophosphamide in Patients With Refractory Multiple Myeloma Who Have Received Lenalidomide and Bortezomib
- Status
- TERMINATED
- Phase
- PHASE2
Bortezomib, Isatuximab, Cyclophosphamide and Dexamethasone Induction in Transplant-Eligible Multiple Myeloma Patients With Renal Insufficiency
- Status
- RECRUITING
- Phase
- PHASE2
BCMA and CD19 Targeted Fast Dual CAR-T for BCMA+ Refractory/Relapsed Multiple Myeloma
- Status
- UNKNOWN
- Phase
- EARLY_PHASE1
Zn-DDC to Target Hypoxia-NFkappaB-CSCs Pathway in Multiple Myeloma
- Status
- RECRUITING
- Phase
- N/A
Phase II Study of Daratumumab Pre-Mobilization and Post-ASCT in Multiple Myeloma
- Status
- WITHDRAWN
- Phase
- PHASE2
Frailty Score-guided Dosing of Lenalidomide, Dexamethasone and Daratumumab Induction Therapy
- Status
- WITHDRAWN
- Phase
- PHASE2
Ixazomib, Lenalidomide, and Combination for Maintenance in NDMM Patients
- Status
- COMPLETED
- Phase
- PHASE4
A Study of AZD0466 in Patients With Advanced Hematologic or Solid Tumors
- Status
- TERMINATED
- Phase
- PHASE1
Amplification of Zinc Finger Protein 217 Gene in Multiple Myeloma
- Status
- UNKNOWN
- Phase
- NA
A Study to Evaluate the Safety of bb2121 in Subjects With High Risk, Newly Diagnosed Multiple Myeloma (NDMM)
- Status
- COMPLETED
- Phase
- PHASE1
Treatment of Hematological Malignancy With Novel CAR-T Cells.
- Status
- UNKNOWN
- Phase
- EARLY_PHASE1
Determining Normal Range for Free Light Chains in Serum Among Twins
- Status
- COMPLETED
- Phase
- NA
Clinical Trial of BCMA CAR T Cell Infusion in Patients With BCMA-positive r/r Multiple Myeloma
- Status
- UNKNOWN
- Phase
- EARLY_PHASE1
Study of HPN217 in Participants With Relapsed/Refractory Multiple Myeloma MK-4002 (MK-4002-001)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
A Study of BCMA/CD19 Dual-Target CAR-T Cell Immunotherapy for Relapsed or Refractory Multiple Myeloma
- Status
- UNKNOWN
- Phase
- EARLY_PHASE1